Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ethinylestradiol + drospirenone
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ethinylestradiol + drospirenone is a combined oral contraceptive (COC) medication consisting of a synthetic estrogen (ethinylestradiol) and a fourth-generation progestin (drospirenone). Drospirenone is a spironolactone analogue that possesses unique anti-mineralocorticoid and anti-androgenic properties, which help to counteract estrogen-related water retention and treat androgen-mediated symptoms such as acne and hirsutism. In the context of research conducted by Ege University, this combination is being specifically evaluated for its impact on psychological comorbidities, including anxiety and depression, in adolescent patients with polycystic ovary syndrome (PCOS). The treatment aims to regulate hormonal imbalances and menstrual cycles while the study monitors changes in mental health outcomes over a six-month period.
- Brand names
- YasminYazSyedaOcellaZarah
- Other names
- ethinylestradiol/drospirenoneEE/DRSP
02
Targets
MR (Mineralocorticoid receptor)ER (Estrogen receptor)PR (Progesterone receptor)AR (Adrenergic receptors)
Beyond the preview
Go deeper on ethinylestradiol + drospirenone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ethinylestradiol + drospirenone.